Coagulation inhibitor replacement in sepsis is a potentially useful clinical approach.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Critical Care Medicine

• Publication date

  2000-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00003246-200009001-00015PMID 11007202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Septic shock in humans

  2020cited by this paper
• clinical investigations in critical care Time Course of Hemostatic Abnormalities in Sepsis and its Relation to Outcome *

  2006cited by this paper
• Purpura fulminans in severe congenital protein C deficiency: Monitoring of treatment with protein C concentrate

  2005cited by this paper
• Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases

  2005cited by this paper
• RECOMBINANT HUMAN ACTIVATED PROTEIN C (rhAPC) PRODUCES A TREND TOWARD IMPROVEMENT IN MORBIDITY AND 28 DAY SURVIVAL IN PATIENTS WITH SEVERE SEPSIS

  1999cited by this paper
• Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin.

  1999cited by this paper
• Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin.

  1999cited by this paper
• Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

  1998cited by this paper
• EFFECT OF ANTITHROMBIN III SUPPLEMENTATION ON INFLAMMATORY RESPONSE IN PATIENTS WITH SEVERE SEPSIS

  1998cited by this paper
• Antithrombin: Its Physiological Importance and Role in DIC

  1998cited by this paper
• Derangements of Coagulation and Fibrinolysis in Critically III Patients with Sepsis and Septic Shock

  1998cited by this paper
• Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock

  1998influential reference
• Relation between dicrotic notch and mean pulmonary artery pressure studied by using a Swan-Ganz catheter in critically ill patients

  1998cited by this paper
• Antithrombin III in Animal Models of Sepsis and Organ Failure

  1998cited by this paper
• Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy.

  1998cited by this paper
• Attenuation of Tissue Thrombosis and Hemorrhage by ala-TFPI Does not Account for Its Protection against E. coli

  1998cited by this paper
• RANDOMIZED, BLINDED, PLACEBO‐CONTROLLED TRIAL OF TISSUE FACTOR PATHWAY INHIBITOR IN PORCINE SEPTIC SHOCK

  1998cited by this paper
• Therapeutic Use of Antithrombin Concentrate in Sepsis

  1998cited by this paper
• Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis.

  1998cited by this paper
• Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats.

  1998cited by this paper
• Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

  1998cited by this paper
• Clinical Experience with Antithrombin III Concentrates in Critically III Patients with Sepsis and Multiple Organ Failure

  1998cited by this paper
• Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.

  1998cited by this paper
• Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium.

  1997cited by this paper
• Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment.

  1997influential reference
• Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans.

  1997cited by this paper
• New therapies in sepsis.

  1997cited by this paper
• ATTENUATION OF ENDOTOXIN‐INDUCED PULMONARY VASCULAR INJURY BY ANTITHROMBIN III.: 653

  1997cited by this paper
• Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway.

  1997cited by this paper
• ANTITHROMBIN III SUPPLEMENTATION IN SEVERE SEPSIS: BENEFICIAL EFFECTS ON ORGAN DYSFUNCTION

  1997cited by this paper
• Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion.

  1997cited by this paper
• Role of cytokines in sepsis.

  1997cited by this paper
• Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor- dependent coagulation pathway

  1996cited by this paper
• Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor.

  1996cited by this paper
• The effect of heparin on the regulation of factor Vila‐tissue factor activity by tissue factor pathway inhibitor

  1996cited by this paper
• ALTERATIONS IN COAGULATION AND FIBRINOLYSIS DURING SEPSIS

  1996cited by this paper
• Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.

  1996cited by this paper
• Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies.

  1996cited by this paper
• Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.

  1996cited by this paper
• Replacement Therapy with a Monoclonal Antibody Purified Protein C Concentrate in Newborns with Severe Congenital Protein C Deficiency

  1995cited by this paper
• Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses.

  1995cited by this paper
• Activation of the protein C pathway in acute sepsis.

  1995cited by this paper
• Treatment of purpura fulminans in meningococcemia with protein C concentrate.

  1995cited by this paper
• A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.

  1995cited by this paper
• Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats.

  1995cited by this paper
• Recombinant Human Soluble Thrombomodulin Reduces Endotoxin-Induced Pulmonary Vascular Injury Via Protein C Activation in Rats

  1995cited by this paper
• Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide.

  1994cited by this paper
• Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock.

  1994cited by this paper
• Thrombogenicity of the Injured Vessel Wall – Role of Antithrombin and Heparin

  1994cited by this paper
• Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.

  1994cited by this paper
• Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.

  1993cited by this paper
• Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

  1993cited by this paper
• Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate.

  1993cited by this paper
• Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.

  1992influential reference
• The effect of leukocyte elastase on tissue factor pathway inhibitor.

  1992cited by this paper
• C4b-binding protein exacerbates the host response to Escherichia coli.

  1991cited by this paper
• Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction.

  1991cited by this paper
• DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage.

  1991cited by this paper
• A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.

  1991cited by this paper
• Protein C, Protein S and c4b-Binding Protein in Severe lnfection and Septic Shock

  1991cited by this paper
• Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells.

  1991cited by this paper
• A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis

  1991cited by this paper
• Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy.

  1990cited by this paper
• Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells.

  1990cited by this paper
• Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation.

  1989cited by this paper
• The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease.

  1989cited by this paper
• Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome.

  1989cited by this paper
• Therapeutic Use of Antithrombin III in Shock and Disseminated Intravascular Coagulation

  1989cited by this paper
• Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells.

  1989cited by this paper
• Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reaction.

  1989cited by this paper
• Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).

  1988cited by this paper
• Characterization of the inhibition of tissue factor in serum.

  1987cited by this paper
• Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.

  1987cited by this paper
• Substitution of antithrombin III in shock and DIC: a randomized study.

  1985cited by this paper
• Antithrombin-III transfusion in disseminated intravascular coagulation.

  1978cited by this paper
• Antithrombin 3. Protection against death after injection of thromboplastin.

  1969cited by this paper
• Antithrombin III: Protection against Death after Injection of Thromboplastin

  1969cited by this paper

• Comparison of fondaparinux sodium and low molecular weight heparin in the treatment of hypercoagulability secondary to traumatic infection.

  2015cites this paper
• Heatstroke in dogs in southern Germany

  2014cites this paper
• Hitzschlag bei Hunden in Süddeutschland

  2014cites this paper
• CHAPTER 38 – Sepsis

  2010cites this paper
• Sp1 is an essential transcription factor for LPS-induced tissue factor expression in THP-1 monocytic cells, and nobiletin represses the expression through inhibition of NF-kappaB, AP-1, and Sp1 activation.

  2008cites this paper
• Perspektiven der adjuvanten Sepsistherapie - hat das Konzept der spezifischen Immunmodulation versagt?

  2006cites this paper
• Heatstroke in small animal medicine: a clinical practice review

  2006cites this paper
• Immunmodulierende Therapien bei der Sepsis: Irrwege der Vergangenheit?

  2005cites this paper
• Use of Drotrecogin Alfa (Activated) in Bariatric Surgery Patients with Severe Sepsis Syndrome: Experience in an Urban Community Teaching Hospital

  2004cites this paper
• Thrombin Induces Nitric-oxide Synthase via Gα12/13-coupled Protein Kinase C-dependent I-κBα Phosphorylation and JNK-mediated I-κBα Degradation*

  2003cites this paper
• Coagulation dysfunction in sepsis and multiple organ system failure.

  2003cites this paper
• Regulation of tissue factor and inflammatory mediators by Egr-1 in a mouse endotoxemia model.

  2003cites this paper
• Thrombin induces nitric-oxide synthase via Galpha12/13-coupled protein kinase C-dependent I-kappaBalpha phosphorylation and JNK-mediated I-kappaBalpha degradation.

  2003cites this paper
• Coagulation Abnormalities in Critical Illness

  2002cites this paper
• Antithrombin: a new look at the actions of a serine protease inhibitor

  2002cites this paper
• Liver in sepsis and systemic inflammatory response syndrome.

  2002cites this paper
• Altering Heparin Cofactor II at VAL439 (P6) either Impairs Inhibition of Thrombin or Confers Elastase Resistance

  2002influential citation
• Importance of underlying mechanism and genotype on outcome of sepsis trials.

  2001cites this paper
• Recombinant Human Activated Protein C, Drotrecogin Alfa (activated): A Novel Therapy for Severe Sepsis

  2001cites this paper
• Hepatic response to sepsis: Interaction between coagulation and inflammatory processes

  2001cites this paper
• Microvascular Alterations in Sepsis

  2001cites this paper